secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2023-01-25T23:59:59+00:00
Accession:  0001683168-23-000307
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharma announces 1-for-12 reverse stock split to meet Nasdaq bid price requirement
--------------------------------------------------------------------------------

- Board set ratio at 1-for-12; effective 12:01 a.m. ET Jan 26, 2023.
- Outstanding shares reduced from ~13.7M to ~1.1M; no change to par value or voting rights.
- Fractional shares paid in cash at $6.51/share based on 10-day average closing price.
- Reverse split aimed at ensuring compliance with Nasdaq minimum $1.00 bid price requirement.
- New CUSIP number 71880W402; trading symbol remains PHIO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316823000307/0001683168-23-000307-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316823000307/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-000307

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer